Phase 3CompletedINTERVENTIONAL
Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.
ClinicalTrials.gov · NCT01178996 · Registry updated: 2010-08-10
- Condition / research focus
- Chronic Hepatitis C
- Sponsor
- sigma-tau i.f.r. S.p.A.
- Countries with listed sites
- France · Germany · Greece · Italy · Spain
- Registry dates and results
- Start: 2004-12. Completion: 2009-07 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Thymosin alpha 1 (biological) — also listed as: Zadaxin
- Ribavirin (drug) — also listed as: Copegus
- PEGinterferon alfa2a (biological) — also listed as: Pegasys
- Placebo (drug)
Where the study takes place — 9 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Hôpital Necker
Paris, France
Site recruitment: Not reported - Universitätsklinikum Tübingen
Tübingen, Germany
Site recruitment: Not reported - University Hospital of Ioannina
Ioannina, Greece
Site recruitment: Not reported - Ospedale Casa Sollievo della Sofferenza
San Giovanni Rotondo, Foggia, Italy
Site recruitment: Not reported - Policlinico S.Orsola-Malpighi
Bologna, Italy
Site recruitment: Not reported - Ospedale Cardarelli
Naples, Italy
Site recruitment: Not reported - Università Cattolica del Sacro Cuore
Rome, Italy
Site recruitment: Not reported - Dipartimento Medico Chirurgico delle Malattie dell'Apparato Digerente e della Nutrizione, Azienda Ospedaliera S Giovanni Battista
Turin, Italy
Site recruitment: Not reported - Hospital del Mar
Barcelona, Spain
Site recruitment: Not reported